Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

42Weighted average common shares outstanding  – diluted

77,852,15449,629,07971,956,29847,214,142Non-GAAP Financial MeasureTo supplement our condensed consolidated financial statements, which statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America (GAAP), we use a non-GAAP financial measure called non-GAAP earnings or loss per share. We define non-GAAP earnings or loss per share as net income or loss not including the impact of:

  • non-cash items (amortization of deferred financing costs and debt discount, stock-based compensation, and change in fair value of derivative liabilities); loss from discontinued operations and gain on sale of business unit.

  • It should be noted that basic and diluted weighted average shares are determined on a GAAP basis and the resulting share count is used for computing both GAAP and non-GAAP basic and diluted earnings per share.

    With the adoption of ASC 815 and its very substantial impact on our total liabilities including certain non-cash derivative liabilities and corresponding reported net gains and losses arising from changes in the underlying market value of our common stock, we believe that non-GAAP earnings or loss per share provides meaningful supplemental information regarding our performance by excluding certain expenses that may not be indicative of the core business operating results and may help in comparing current-period results with those of prior periods as well as with our peers. We present this information to investors as an additional tool for evaluating our financial results in a manner that reflects ongoing operations and facilitates comparisons with operating results from prior periods.  The presentation of this additional non-GAAP information is intended to provide investors with additional incremental tools for their review of our results and is not meant to be considered in isolation or as a
    '/>"/>

    SOURCE Cardium Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
    2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
    3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
    4. Cardium Regains Listing Compliance With NYSE Amex
    5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
    6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
    7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
    8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
    9. Cardium Completes $6.0 Million Registered Direct Offering
    10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
    11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014  Neogen Corporation (Nasdaq: ... into a strategic agreement with Merck Animal Health to ... The Igenity Dairy Heifer Program consists of ... on the genetic potential of replacement dairy heifers. The ... is born, and is an excellent tool in the ...
    (Date:9/18/2014)... 18, 2014 SeqLL Inc., the ... technology, announced today the closing of a $1M ... by Genomic Diagnostic Technologies, will increase the power ... , Founded in March 2013 by Daniel Jones, ... at Helicos BioSciences, SeqLL has continued to offer ...
    (Date:9/18/2014)... touch in the course of a day - ... rely on the chemical industry to turn raw ... products into valuable chemicals that are the ingredients ... Sarina Sarina, who achieved outstanding progress in driving ... temperature using light instead of fossil fuels, has ...
    (Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
    Breaking Biology Technology:Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
    ... Sept. 14 Savient Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated ... chronic gout in adult patients refractory to conventional therapy. ... in patients who have failed to normalize serum uric ...
    ... SUNNYVALE, Calif., Sept. 14 Molecular Devices, Inc., ... analysis, today announced the launch of two new ... microplate readers, enabling the company to meet all ... future. (Logo:   http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) ...
    ... 2011 Fiscal Year Guidance -- HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
    Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 2Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8
    (Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
    (Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
    (Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
    Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
    ... time of the Babylonians to the Incas, terracing has ... hilly croplands. Designing terrace layouts can be time consuming ... developing a Web-based program that will design multiple farm ... help farm experts choose the most efficient and cost-effective ...
    ... think of Earth as a nurturing place, straining mightily to maintain ... Gaia hypothesis, named for the ancient Greek goddess of Earth, even ... of giant organism, with its complex systems finely tuned to compensate ... is the Gaia view that is out of kilter, says Peter ...
    ... National Institutes of Health is launching the first ... for rare and neglected diseases. The $24 million ... for Rare and Neglected Diseases Program, or TRND. ... spring, is unusual because TRND creates a drug ...
    Cached Biology News:Web-based program designs more efficient farm terrace layouts 2New book suggests Earth perhaps not such a benevolent mother after all 2New book suggests Earth perhaps not such a benevolent mother after all 3NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
    Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
    Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
    Goat polyclonal to Centaurin alpha 2**...
    ... immobilization can be coupled with a ligand such ... create an affinity matrix of choice. Affi-Gel 10 ... amines. Affi-Gel 10 gel couples neutral or basic ... 15 gel couples acidic proteins with pI less ...
    Biology Products: